Pioglitazone and SGLT2 Inhibitors vs. DPP4 Inhibitors in Patients With Stroke

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

Also called NCT04419337

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04419337
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Taiwan (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04419337. Randomized; no masking; primary purpose treatment. Start 2019-09-15 (actual); primary completion 2023-07-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Pioglitazone and SGLT2 Inhibitors vs. DPP4 Inhibitors in Patients With Stroke
Condition
Diabetes Mellitus
Condition
Stroke
Intervention (Drug)
Metformin plus Pioglitazone plus an SGLT2 inhibitor
Lead sponsor
Chang Gung Memorial Hospital (class: other)
Collaborator
National Taiwan University Hospital (class: other)
Collaborator
Chiayi Christian Hospital (class: other)
Collaborator
Tainan Sin-lau Hospital (class: not stated)

Record details

Record id
cardio:ct-nct04419337
Content hash
6891a8d00344fc5c74de9317ea0cfda3f885be25a1c66257f2e7e88b3943ce2e